表纸
市场调查报告书

人类胚胎干细胞的全球市场

Human Embryonic Stem Cells Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品编码 567966
出版日期 内容资讯 英文 120 Pages
商品交期: 2-3个工作天内
价格
Back to Top
人类胚胎干细胞的全球市场 Human Embryonic Stem Cells Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年02月01日内容资讯: 英文 120 Pages
简介

本报告提供人类胚胎干细胞的全球市场调查,市场概要,各应用领域、地区的市场趋势,市场促进、阻碍因素及课题分析,竞争情形,主要企业简介等系统性资讯。

第1章 简介

  • 市场定义
  • 调查手法

第2章 摘要整理

第3章 主要推论

第4章 市场概要

  • 市场概况
  • 波特的五力分析

第5章 市场动态

  • 推动因素
  • 阻碍因素
  • 市场机会
  • 课题

第6章 市场区隔

  • 人类胚胎干细胞的全球市场:各应用领域
    • 再生医疗
    • 干细胞生物学
    • 组织工程
    • 毒性实验
  • 人类胚胎干细胞的全球市场:各地区
    • 北美
    • 欧洲
    • 亚太地区
    • 中东、非洲
    • 南美

第7章 竞争情形

  • 合并、收购
  • 新产品的投入
  • 协定、联盟、合作

第8章 企业简介

  • Australian Stem Cell Centre
  • BD Biosciences
  • Cellartis AB
  • Millipore Corporation
  • Geron Corporation
  • Invitrogen Corporation
  • Viacyte
  • SA Biosciences Corporation
  • Tataa Biocenter
  • Thermo Scientific
  • Vitrolife AB

第9章 市场未来展望

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: 54446

The government funding for the development of regenerative medicine has been increasing in most developed countries, because of its applications in organ transplantation, tissue engineering, and various other applications. In the United States, two major government agencies, National Institutes of Health (NIH) and California Institute of Regenerative Medicine (CIRM), fund almost all the translational researches and regenerative medicine development in the country. It is estimated that the United States government invests around USD 800-900 million every year in stem cell research. Additionally, other factors such as the high prevalence of cardiac and malignant diseases, and rising demand for regenerative medicines are expected to drive the market.

Key Market Trends

Stem Cell Biology Research Segment is Expected to Show Better Growth in the Forecast Years

Based on the application, it is segmented into regenerative medicine, stem cell biology research, tissue engineering, and toxicology testing. Stem cell biology research will show better growth, owing to the high prevalence of cardiac and malignant diseases. An article published by the ISSCR (International Society for Stem Cell Research) reported that the stem cells hold potential for the treatment of Parkinson's disease in humans. Recently, one of the market players, International Stem Cell Corporation (ISCO), received the patent covering methods for generating HLA homozygous parthenogenetic human stem cell lines from unfertilized eggs. The patent was issued in Australia. Furthermore, to boost the pace of stem cell research, the government is providing funding opportunities to researchers. Thus, owing to these factors, the market studied is expected to witness a high growth rate over the forecast period.

North America Dominates the Human Embryonic Stem Cells Market

The human embryonic stem cells market is expected to dominate in the North America region owing to extensive research activities, along with high burden of chronic diseases and genetic disorders in the region. The United States also shows a high incidence of other diseases, such as diabetes, heart disease, renal failure, and osteoporosis. Human embryonic stem cells have high potential for use in treatment and may become a standard of care for these diseases. Additionally, the FDA has approved clinical trials, which indicated the use of stem cells. Hence, these factors are expected to influence the growth of the human embryonic stem cells market over the forecast period.

Competitive Landscape

The global players into the human embryonic stem cells market are Becton, Dickinson and Company, Cynata Therapeutics Limited, ESI BIO, Geron Corporation, International Stem Cell Corporation, Merck KGaA, PromoCell GmbH, STEMCELL Technologies Inc, Thermo Fisher Scientific and ViaCyte, Inc.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 High Prevalence of Cardiac and Malignant Diseases
    • 4.2.2 Rising Demand for Regenerative Medicines
    • 4.2.3 Increasing Support from Governments and Government and Private Institutions
  • 4.3 Market Restraints
    • 4.3.1 High Cost of the Procedure
    • 4.3.2 Stringent Regulatory Guidelines
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Application
    • 5.1.1 Regenerative Medicine
    • 5.1.2 Stem Cell Biology Research
    • 5.1.3 Tissue Engineering
    • 5.1.4 Toxicology Testing
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Rest of World

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Becton, Dickinson and Company
    • 6.1.2 Cynata Therapeutics Limited
    • 6.1.3 ESI BIO
    • 6.1.4 Geron Corporation
    • 6.1.5 International Stem Cell Corporation
    • 6.1.6 Merck KGaA
    • 6.1.7 PromoCell GmbH
    • 6.1.8 STEMCELL Technologies Inc
    • 6.1.9 Thermo Fisher Scientific
    • 6.1.10 ViaCyte, Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top